ABSTRACT
Status epilepticus (SE) is a frequent life-threatening neurologic emergency 1 ; rapid and effective treatment is advocated. Treatment guidelines 2,3 recommend a stepwise approach. Randomized controlled trials 4, 5 have demonstrated the role of benzodiazepines (BZDs) as initial treatment. If this fails, guidelines recommend the use of a nonsedative antiseizure drug (ASD), and when SE is refractory, continuous IV anesthetic drugs (CIVADs) should be considered to induce therapeutic coma (TC), especially in convulsive SE. The available evidence to guide clinical decision-making is nevertheless of low level. 1 The rationale of using TC is to stop seizure activity to hypothetically prevent seizure-induced brain damage and to reduce cerebral metabolism 6 ; however, supporting data are missing. 7 TC is resource-consuming: it requires an intensive care unit (ICU) and continuous EEG. 8 Moreover, CIVADs are related to rare but potentially serious side effects, such as hemodynamic instability, propofol infusion syndrome, propylene glycol toxicity (a vehicle for many anesthetic drugs), and bowel ischemia. 9 In the context of limited evidence supporting the practice of TC and the unfavorable side-effect profile, recent retrospective observational studies [10] [11] [12] suggested that TC may be independently associated with increased mortality. While these studies are not yet sufficient to change clinical practices, they have raised important questions.
Given the current uncertainty, our aim was to compare different policies of TC use for SE management, in the sense of a natural experiment, and its potential effect on mortality and hospital length of stay (LOS), using a prospective multicenter SE registry. Since all patients with suspected SE have an EEG within 24 hours in all centers, patients were screened daily through EEG requests. Inclusion criteria were checked (V.A. for HAH; A.O.R., J.N. for CHUV) on a daily basis. The authors have already collaborated on several projects related to SE, 13, 14 ensuring a uniform process for data collection.
SE was defined as an ongoing seizure lasting more than 5 minutes, or by repeated seizures without complete recovery inbetween. 2 In case of nonconvulsive SE, EEG criteria were used. 15 Treatment protocol. The 4 hospitals have local treatment protocols based on current US and European guidelines. 2, 3 Details can be found in a previous publication.
14 Briefly, a BZD is advocated as first line, with HAH favoring lorazepam or midazolam and CHUV using preferentially clonazepam. Second, an urgent seizure-control medication is recommended with a nonsedative ASD (phenytoin or fosphenytoin, valproic acid, levetiracetam, or lacosamide). In case of refractory SE, TC using propofol and/or midazolam, or barbiturates, is recommended, especially for convulsive SE. In case of a nonconvulsive SE, an additional line of nonsedative ASD is recommended before considering TC.
Definition of variables. We collected demographics and worst seizure type (categorized in increasing order of severity as absence seizures, myoclonic seizures in genetic generalized epilepsy, focal seizure without or with consciousness impairment, and generalized convulsive seizures, or nonconvulsive SE in coma [NCSEC] ; generalized convulsive SE and NCSEC were grouped into one category for analysis, as they represent the 2 most severe types of seizures). SE severity was assessed using the STESS (Status Epilepticus Severity Score) for every patient 16 ranging from 0 to 6 (see figure e-1 at Neurology.org for more details). Also, for each patient, the Charlson Comorbidity Index (CCI) was retrieved based on comorbidities known on admission, 17 excluding SE etiology. CCI is a validated measure based on 17 common medical conditions with scores ranging from 0 to 33 (see figure e-2 for more details).
The beginning time for SE was determined using prehospital charts and emergency department summaries. For SE episodes without clear onsets (unwitnessed, subtle nonconvulsive SE), the time last seen well was considered as the beginning of SE. Each treatment line, including out-of-hospital medication, was prospectively recorded using premedical, emergency, and in-hospital patient records, including the drug used, total loading (repeated doses given before introduction of the next line of treatment was considered as a total loading dose), maintenance dose (highest prescribed dose), and timing of administration. Initial ASD treatment was considered adequate if local recommendations were followed in terms of sequence (meaning a BZD first and then a nonsedative ASD) and in terms of dosage (within a range of 625% of the recommended dose, as previously described).
14 Patients were counted as having received TC only if CIVADs were used to treat seizures: use of TC was not considered if CIVADs were administered to maintain sedation in a patient intubated for airway protection, as previously described. 12 SE was considered as refractory if persisting despite the first 2 treatment lines. 2 It was considered as controlled after the last clinical or electrical seizure without recurrence for 48 hours, following weaning of sedative medication. Clinical outcome at hospital discharge was assessed using hospital discharge summaries. All data except for the CCI were prospectively collected.
Primary and secondary outcomes. The rate of TC use was the primary outcome. Mortality and LOS of survivors in acute facilities were considered as secondary outcomes.
Standard protocol approvals, registrations, and patient consents. The institutional review boards of each center approved this study. Because this observational study involved no risk for patients and focused on acutely ill patients, consent was waived.
Statistical analysis. The data were separately summarized for both groups (CHUV and HAH). Continuous variables were described by mean and SD, or median and interquartile range, depending on distribution of variables. Categorical variables were described by frequencies. The 2 hospital groups were compared using x 2 , Wilcoxon rank sum, or Student t tests, as required. Associations of different clinically relevant variables with the use of TC and with mortality were assessed using univariate logistic regression. Variables with p value ,0.2 (with age, sex, cohort, or use of TC being forced into models because of primary interest) were entered into a stepwise, backward procedure to fit a multivariable logistic regression model. A similar analysis was performed for the duration of hospitalization of survivors, using a negative binomial regression model. Linearity of continuous covariates was checked using fractional polynomials.
Model diagnostics were performed as a post estimation step (influence statistics, deviance residuals, leverages, Pearson or Hosmer-Lemeshow goodness-of-fit tests, as required). Because the LOS is greater than zero and attributable to overdispersion, the negative binomial regression model was compared to the Poisson regression model using the countfit Stata command that allows informal assessment of the fit of count models by plotting observed-predicted vs counts. In addition, likelihood ratio test of overdispersion and Vuong test were performed to compare the 2 models. Discrimination was tested using the area under the receiver operating characteristic (ROC) curve. Results with a p value ,0.05 were considered statistically significant. Calculations were performed using Stata version 12 (StataCorp, College Station, TX).
RESULTS During the study period, 236 SE episodes in the CHUV and 126 in the HAH were identified. Both groups were homogeneous in demographics, comorbidities, SE characteristics, and etiologies (table 1) . Initial treatments were more often in line with local guidelines at the CHUV than in HAH (42.8% vs 11.9%), and patients treated in HAH received significantly more ASDs (3 vs 2) and TC (25.4% vs 9.75%). However, when TC was used, it occurred within a similar delay from SE start and after a similar number of ASDs. Outcomes were similar in terms of mortality (14% vs 15%) and LOS (10 vs 9 days). Approximately half of the patients (52%) in the CHUV and more than a third (32.6%) in HAH were back to their clinical premorbid baseline at hospital discharge. Table 2 displays associations between the use of TC and all clinically relevant variables. The multivariable logistic regression model shows that TC was independently associated with younger age, lower CCI, increasing STESS, SE refractoriness, and hospital group. This model had an excellent goodness-of-fit (Hosmer-Lemeshow: p 5 0.859, x 2 5 316.8). The area under the ROC curve was 0.85 (95% confidence interval 0.80-0.90). Figure 1 displays adjusted margin probabilities for the use TC by hospital groups, SE refractoriness, STESS, and CCI (Hosmer-Lemeshow goodness-of-fit test: 0.86): the likelihood of TC was higher in HAH overall, for refractory SE, for all STESS between 1 and 5, and for all CCI #4.
Several clinically relevant variables including demographics and SE characteristics (severity, type of seizure, etiology, and duration) were significantly associated with mortality in univariate logistic regression analysis (table 3). In the multivariate logistic regression model, increasing CCI and STESS, a potentially fatal etiology, and refractory SE remained associated with mortality. Of note, the use DISCUSSION This cohort study performed as a natural experiment shows that there are major differences in the TC use between the 2 groups. Our study provides Class III evidence that after controlling for SE severity and patient comorbidities, TC was much more frequent in the Boston hospitals as compared to the Swiss center (adjusted odds ratio: 11.3). While there was no increase of mortality with TC, it was associated with increased duration of acute hospitalization.
The difference in TC preference between sites may be explained by several factors. First, in the context of relatively weak evidence supporting it, there may be cultural differences and different practice habits across different centers. Observational SE studies have reported different rates of CIVAD prescription: 5% in Germany, 18 8% in Italy, 19 10.7% 12 in Switzerland, 22% in France, 20 and up to 31% 21 or 36% in the United States. 22 The same is true when describing treatment of refractory SE: CIVADs were used in 30% 23 and 43% 24 of patients in Switzerland, as opposed to 87.3% in the United States. 25 Three recent studies performed in the United States and Switzerland [10] [11] [12] have questioned the risk/benefit ratio of TC, with observational data showing an independent association with worse outcome after correction for major confounders. Nevertheless, more aggressive treatment, including TC, is recommended by some experts. 26, 27 Another explanation may be that the more frequent inadequacy of initial treatment in HAH as compared to current guidelines, mostly attributable to lorazepam underdosing, 14 might lead to an increased need for CIVADs following SE refractoriness. Adequate initial treatment is indeed associated with more rapid seizure cessation. 20 However, association between use of TC and inadequate initial ASD was not found, possibly reflecting the confounding action of further treatment. Furthermore, our group previously showed that treatment inadequacy has no significant influence on mortality. 28 Finally, the systematic use of continuous EEG in HAH, which is more common than in Europe, may influence treatment choices: electrographic seizures could have been missed in some patients at CHUV, preventing treatment escalation. Breakdown of seizure types was remarkably similar between the 2 groups, except that NCSEC was more frequent in HAH, supporting this hypothesis. However, because temporal relationships between the start of EEG recordings and treatment were not recorded, this hypothesis remains unproven.
TC was not associated with mortality after controlling for demographics, SE severity, refractoriness, and comorbidities but correlated to a 60% increase in the LOS in acute facilities. Ten years ago, the median direct cost of an inpatient hospital stay for SE has been estimated at up to $1,458 US dollars per day 29 ; any increase in duration of hospital stay may thus exert an important effect on health care costs.
Mortality was mainly related to SE severity, etiology, comorbidities, and refractoriness, in line with several previous studies, 30, 31 but not TC. Besides the aforementioned possible relationship of TC to increased mortality, [10] [11] [12] which has been questioned in view of methodologic limitations, 32 one recent review demonstrated a high rate of infectious complications after CIVADs (.50%). 33 Two other studies did not show a TC influence on mortality in particular subtypes of SE-new-onset refractory SE 34 and NCSE. 35 Finally, one study modeling decisionmaking on the aggressiveness of treatment of nonconvulsive SE in the ICU showed that, even in cases in which NCSE was thought to cause brain damage, aggressive treatment may yet confer a greater overall risk. 36 Of interest, a randomized study from India assessed treatment protocols avoiding CIVADs in the context of ICU nonavailability 37 : 92% of patients with generalized convulsive SE could avoid CIVADs (used in their protocol as a fifth-line rescue therapy after failure of BZD and 3 different nonsedative ASDs); 29% of SE episodes were considered refractory; and mortality was 13.6% overall and 25.6% for refractory SE, in line with studies from Western countries. 23, 30 As such, there is still a major controversy as to whether TC increases mortality or improves outcome. TC seems, however, independently related to an increased LOS, according to our data, and infections. 12 Because of these considerations, we believe that our findings reinforce the call for a well-conducted evaluation of the role of TC in the treatment of SE, going beyond short-term survival after SE. 32 A subset of patients from CHUV included in this analysis was also part of a previous study showing an independent increase of mortality associated with the use of TC. 12 When combined with the HAH group, TC seemed to lose this negative effect. There are several possible explanations. First, the significant influence on mortality was strongest for SE types other than generalized convulsive SE or NCSEC at the time of treatment in the Swiss study, meaning that patients with initial generalized convulsive SE evolving into focal SE were included in the more benign SE forms for analysis, as opposed to the present study, which categorized patients according to the worst seizure type. Second, the negative effect of TC may have been lost because more benign forms of SE with favorable outcome were treated with CIVADs in HAH as opposed to at CHUV, where TC is usually reserved for more severe SE. Also, the increase of mortality associated with TC in the aforementioned study 12 may be attributable to an unrecognized and as-yet unmeasurable factor influencing mortality and the clinician's decision to put a patient in a TC. Finally, the vast majority of patients in Boston were treated in a neuro-ICU, as opposed to patients in Switzerland, treated in a multidisciplinary ICU with a consultant neurologist. Neurointensivists may be more aware of systemic complications of CIVADs, although this probably has a minor role, as a neuro-ICU vs multidisciplinary ICU setting did not appear to affect mortality or LOS in SE in a previous study. 38 The strengths of this study include the large number of patients and the first direct comparison of TC use between 2 geographical settings assessed through a systematic and comprehensive, prospective data collection. Moreover, statistical models were constructed in order to strictly include all known relevant outcome predictors. We acknowledge, however, some limitations. First, because of the observational design, we cannot be certain that some unidentified confounder influencing the probability of using TC or mortality was missed. Also, the reasons for death of patients were not systematically assessed. We also cannot exclude the possibility that there was a higher rate of care withdrawal in one group, and we were not able to evaluate whether death occurred because of CIVAD side effects. In a dedicated study, while 106 of 120 deaths after SE were primarily related to the underlying etiology, complications of therapy were considered to contribute to death in one-third of cases. 39 Another important limitation of all studies to date, including this one, is that no one has controlled for the quality or depth of TC. This limitation is important in light of evidence that management of pharmacologically induced coma is highly variable and often fails to achieve therapeutic targets (i.e., EEG burst suppression, seizure suppression, or suppression pattern) (unpublished results of M.B.W.). The potential benefit of TC may be offset in practice by adverse effects associated with over-and underdosing of anesthetics. Finally, because functional outcomes were not assessed based on controlled and validated scores, the data were not sufficient to determine whether there was an independent association with TC.
We show that different policies regarding TC induction for SE management exist, despite relatively uniform treatment guidelines. The more "aggressive" and resource-consuming treatment seems to increase length of hospital stay (and thus costs) without improvement of survival. This appears highly relevant in the context of high daily costs related to management of acutely ill patients and the increased burden of SE. 40 Based on these findings, we recommend that TC should be reserved for severe refractory convulsive SE forms and tailored to the underlying biological background. Also, every effort should be made to improve awareness and translation into practice of SE guidelines, in order to minimize underdosage of the first treatment line. Until an urgently needed randomized trial is performed, SE management should always consider Galen's principle: primum non nocere.
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